[Asu1,6]-Oxytocin

[Asu,]-Oxytocin Research Use Only

Scientific Overview

[Asu,]-Oxytocin is a cyclic peptide analog of oxytocin in which positions 1 and 6 are substituted with Laminosuberic acid (Asu), forming a stabilized ring structure. This modification enhances conformational rigidity and can alter receptor affinity, metabolic stability, and biological activity, making the analog valuable for mechanistic studies in peptide biology.

Researchers use [Asu,]-Oxytocin as a molecular tool in receptor binding studies, structureactivity relationship (SAR) investigations, and biochemical assays involving oxytocinrelated signaling pathways. Its high purity and stable powder form support reproducible results across peptide chemistry, endocrinology, and neurobiology research.

Common Research Applications

• Receptor binding and ligandreceptor interaction studies
• Structureactivity relationship (SAR) investigations
• Peptide signaling pathway research
• Biochemical and enzymatic assays involving oxytocin analogs
• Peptide stability and degradation studies

Usage & Handling Guidance

This peptide is supplied as a lyophilized powder. For experimental use, researchers typically reconstitute [Asu,]-Oxytocin in sterile water, dilute acid, or buffer depending on assay requirements. For longterm stability, aliquoting after reconstitution is recommended to avoid repeated freezethaw cycles.

• Reconstitution: Sterile water, dilute acetic acid, or assaycompatible buffer
• Storage: 20 C (powder); 80 C recommended for longterm storage of solutions
• Handling: Avoid repeated freezethaw cycles

What You Get

• 500 mg of highpurity [Asu,]-Oxytocin
• Stable powder form for flexible experimental use
• Biotechnologygrade peptide
• For research use only (RUO)

Frequently Asked Questions

• Is this product suitable for clinical or diagnostic use? No. This product is for research use only.
• Can I obtain a Certificate of Analysis (COA) or Technical Data Sheet (TDS)? COA and TDS availability depends on the manufacturers current active batch. In many cases, documentation can be provided upon request. Please contact us to inquire about documentation for the specific lot being shipped.
• How should I reconstitute this peptide? Researchers commonly use sterile water, dilute acetic acid, or assayspecific buffers.
• Is this peptide suitable for receptor binding assays? Yes. Oxytocin analogs such as [Asu,]-Oxytocin are frequently used in receptor interaction studies.

References

• Sibilia V, Netti C, Guidobono F, Villa I, Pecile A. Inhibitory effects of centrally administered /ASU1-7/eel calcitonin on basal and stimulated prolactin release in rats J Endocrinol Invest. 1990 Jun;13(6):507-11.
• Bramucci M, Singh M, Nagarajan V. Biotransformation of p-xylene and 2,6-dimethylnaphthalene by xylene monooxygenase cloned from a Sphingomonas isolate Appl Microbiol Biotechnol. 2002 Sep;59(6):679-84.
• Fahrenholz F, Tth G, Crause P, Eggena P, Schwartz IL. [1,6-alpha-aminosuberic acid, 3-(p-azidophenylalanine), 8-arginine] vasopressin: a new photoaffinity label for hydroosmotic hormone receptors. Characterization of the ligand and irreversible stimulation of hydroosmotic water flow in toad bladder by photoaffinity labeling J Biol Chem. 1983 Dec 25;258(24):14861-7.
• Yamaguchi M, Momose K. Effect of calcitonin on fructose 1,6-diphosphatase activity in rat liver: role of cytosolic calcium concentration Horm Metab Res. 1984 Dec;16(12):650-3.
• Minamitani N, Chihara K, Kaji H, Kodama H, Fujita T. Inhibitory effect of [Asu1,7]-eel calcitonin on growth hormone-secretion in conscious, freely moving, male rats Endocrinology. 1985 Jul;117(1):347-53.
• Kaji H, Chihara K, Minamitani N, Kodama H, Kita T, Fujita T. Effect of [Asu1,7]eel calcitonin on prolactin release in normal subjects and patients with prolactinoma Acta Endocrinol (Copenh). 1985 Mar;108(3):297-304.
• Morita T, Yamamoto A, Takakura Y, Hashida M, Sezaki H. Improvement of the pulmonary absorption of (Asu1,7)-eel calcitonin by various protease inhibitors in rats Pharm Res. 1994 Jun;11(6):909-13.
• Zhang H, Wu C, Chen Q, Chen X, Xu Z, Wu J, Cai D. Treatment of obesity and diabetes using oxytocin or analogs in patients and mouse models PLoS One. 2013 May 20;8(5):e61477.
• Morimoto S, Miyauchi A, Fukuo K, Imanaka S, Yamamoto H, Tsuchiya H, Koh E, Yukawa S, Onishi T, Avioli LV, et al. Eel calcitonin suppresses plasma human calcitonin levels in medullary carcinoma of the thyroid Clin Sci (Lond). 1986 Apr;70(4):333-8.